<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Kidney Function &#187; Renal Info</title>
	<atom:link href="http://kidneyfunction.org/category/renal-info/feed/" rel="self" type="application/rss+xml" />
	<link>http://kidneyfunction.org</link>
	<description>Renal Information</description>
	<lastBuildDate>Fri, 30 Jul 2010 02:42:55 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Dangers of Nephrotoxins in the Workplace</title>
		<link>http://kidneyfunction.org/dangers-of-nephrotoxins-in-the-workplace/</link>
		<comments>http://kidneyfunction.org/dangers-of-nephrotoxins-in-the-workplace/#comments</comments>
		<pubDate>Fri, 18 Jun 2010 01:43:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>
		<category><![CDATA[nephrotoxins]]></category>
		<category><![CDATA[occupational renal diseases]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/?p=27229</guid>
		<description><![CDATA[Is your current job putting your kidney health at risk?
According to Clinical Renal Toxicology&#8230;
&#8220;Chemicals can affect the renal function or structures through a direct toxic action or through various systemic effects, such as intravascular hemolysis, rhabdomyolysis, or cardiac failure.&#8221;
Such chemicals include:

Lead
Cadmium
Mercury
Silica

Certain occupations are far more at risk than others. For instance, individuals that work in [...]]]></description>
			<content:encoded><![CDATA[<p>Is your current job putting your kidney health at risk?</p>
<p>According to Clinical Renal Toxicology&#8230;</p>
<p>&#8220;Chemicals can affect the renal function or structures through a direct toxic action or through various systemic effects, such as intravascular hemolysis, rhabdomyolysis, or cardiac failure.&#8221;</p>
<p>Such chemicals include:</p>
<ul>
<li>Lead</li>
<li>Cadmium</li>
<li>Mercury</li>
<li>Silica</li>
</ul>
<p>Certain occupations are far more at risk than others. For instance, individuals that work in brazing or nickel-cadium battery manufacturing are exposed to high levels of Cadium. However, someone working in <a href="http://smartrecycling.com">scrap metal recycling in Los Angeles</a> would also likely be exposed to Cadium in the process of recovering the metal, but not as much as the person working in the manufacturing of nickel-cadium batteries.</p>
<p>Lead is another one you really want to watch out for. Occupations most notorious for causing lead exposure are lead battery manufacturing, soldering, smelting, radio repair, glass &#038; ceramic manufacturing, and also paint stripping (in the case of lead-based paints).</p>
<p>If you are concerned about the health risks associated with your current occupation, especially pertaining to renal health, consult your employer. He or she should have additional details.</p>
<p>Also, check out this in-depth look at <a href="http://www.haz-map.com/renal.htm">occupational renal diseases</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/dangers-of-nephrotoxins-in-the-workplace/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Who Administers Hemodialysis?</title>
		<link>http://kidneyfunction.org/who-administers-hemodialysis/</link>
		<comments>http://kidneyfunction.org/who-administers-hemodialysis/#comments</comments>
		<pubDate>Tue, 11 May 2010 08:08:45 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>
		<category><![CDATA[dialysis]]></category>
		<category><![CDATA[hemodialysis]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/?p=22294</guid>
		<description><![CDATA[



In general, hemodialysis is performed in a dialysis center by technicians trained in the care of patients who are supervised by nurses. Medicare pays three hemodialysis treatments per week. If you choose to undergo treatment at a center, it will be for a fixed schedule, three times a week, on Mondays, Wednesdays and Fridays or [...]]]></description>
			<content:encoded><![CDATA[<p><center><script type="text/javascript"><!--
google_ad_client = "pub-3645316179451463";
/* 468x60, created 5/11/10 */
google_ad_slot = "6633942113";
google_ad_width = 468;
google_ad_height = 60;
//-->
</script><br />
<script type="text/javascript"
src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script></center><br />
In general, hemodialysis is performed in a dialysis center by technicians trained in the care of patients who are supervised by nurses. Medicare pays three hemodialysis treatments per week. If you choose to undergo treatment at a center, it will be for a fixed schedule, three times a week, on Mondays, Wednesdays and Fridays or Tuesdays, Thursdays and Saturdays. If you get the schedule of your choice, you may request to be put on a waiting list for a schedule of your choice. In special cases, you may exchange your time with someone else. You will need to plan well your dialysis program if you work or have children to care. Some centers provide dialysis treatments during the night in the middle. This treatment is done over a longer period at night, while sleeping in the middle. This type of dialysis reduces the limitations on food and fluid intake, and also it provides more time during the day to work, care for their children and do hobbies and other activities.</p>
<p>You can choose to learn to make their own hemodialysis treatments at home. When you are the only patient, it may become more frequent dialysis treatments or lasting almost replaced the normal work performed by healthy kidneys. Daytime hemodialysis at home (DHHD for short in English) is performed 5-7 days a week for 2 to 3 hours per session and you organize the schedule. If your health insurance plan would pay more than three treatments, you could be brief treatments during the morning or afternoon. Nocturnal home hemodialysis (NHHD by its acronym in English) is done in 3-6 nights a week while you sleep. Whether you choose the DHHD or NHHD, this will allow food and a normal fluid intake, with fewer blood pressure medications and other health problems. Most programs ask patients to do home hemodialysis have a skilled attendant during treatments. Learning to be hemodialysis is like learning to drive a car: it takes a few weeks and, initially, is alarming but then becomes a routine. The dialysis center provides the equipment and training, and assistance by phone 24 hours if you have any questions or problems. New machines for home dialysis are smaller and easier to use than the equipment used in schools.</p>
<p>You have options of dialysis centers and many cities have more than one site to choose from. You can visit a center to see if there are treatments you want or the time it needs. Some centers allow the use of laptops or cell phones or receive visits, others not. Medicare has a list of all centers in the United States on its Web site at www.medicare.gov / dialysis (in English), which shows the quality ratings of each school. Your health plan may have a list of sites where you can go. If you choose a treatment option in a school, it must be near your home to reduce your travel time. If the treatment is done at home, once you are trained, you should only go to the center once a month. So, the center can be as far as you want to travel once a month. </p>
<p><strong>Possible Complications of Dialysis</strong><br />
Vascular access problems are the most common reason for hospitalization among people receiving hemodialysis. Some common problems include infection, blockage by clotting and poor circulation. These problems may prevent their treatments to succeed. You might have to undergo repeated surgeries to achieve a properly functioning access.</p>
<p>Other problems may be caused by rapid changes in water and chemical balance of your body during treatment. Muscle cramps and hypotension (a sudden drop in blood pressure) are two common side effects. Hypotension can make you feel weak, dizzy or sick to your stomach.</p>
<p>Probably need a few months to adjust to hemodialysis. Side effects can often be dealt with swiftly and easily, so you should inform your doctor and dialysis staff suffered any side effects. You can avoid many side effects if you follow a proper diet, limiting fluid intake and taking medications as directed.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/who-administers-hemodialysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. M Faulkner on Diabetic Related Kidney Disease</title>
		<link>http://kidneyfunction.org/diabetic-related-kidney-disease-dr-mfaulkner/</link>
		<comments>http://kidneyfunction.org/diabetic-related-kidney-disease-dr-mfaulkner/#comments</comments>
		<pubDate>Fri, 08 Jan 2010 15:24:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>
		<category><![CDATA[kidney failure]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[kidney disease]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org?p=506</guid>
		<description><![CDATA[Comments With Dr. James Haney Presents Dr. MFaulkner and a discussion on Diabetes and Kidney Disease, and what steps need to be taken for individuals to properly protect themselves.
]]></description>
			<content:encoded><![CDATA[<p><center><object width="425" height="344"><param name="movie" value="http://youtube.com/v/Kiw-9VvL2Mc&#038;hl=en&#038;fs=1&#038;"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="http://youtube.com/v/Kiw-9VvL2Mc&#038;hl=en&#038;fs=1&#038;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"></embed></object></center><br />Comments With Dr. James Haney Presents Dr. MFaulkner and a discussion on Diabetes and Kidney Disease, and what steps need to be taken for individuals to properly protect themselves.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/diabetic-related-kidney-disease-dr-mfaulkner/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Living with Kidney Disease &#8211; what you should know</title>
		<link>http://kidneyfunction.org/living-with-kidney-disease-what-you-should-know/</link>
		<comments>http://kidneyfunction.org/living-with-kidney-disease-what-you-should-know/#comments</comments>
		<pubDate>Mon, 14 Dec 2009 19:27:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>
		<category><![CDATA[kidney failure]]></category>
		<category><![CDATA[kidney disease]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org?p=490</guid>
		<description><![CDATA[Module 2 Chapter 7. This is the first chapter of the 2nd DVD about living with Kidney Disease. It is a Health awareness/education project designed to support anyone who has been told by their doctor that they have some level of kidney Disease. The 2nd module offers practical advice for those patients with advanced kidney [...]]]></description>
			<content:encoded><![CDATA[<p><center><object width="425" height="344"><param name="movie" value="http://youtube.com/v/7DgHr-fCzfQ&#038;hl=en&#038;fs=1&#038;"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="http://youtube.com/v/7DgHr-fCzfQ&#038;hl=en&#038;fs=1&#038;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"></embed></object></center><br />Module 2 Chapter 7. This is the first chapter of the 2nd DVD about living with Kidney Disease. It is a Health awareness/education project designed to support anyone who has been told by their doctor that they have some level of kidney Disease. The 2nd module offers practical advice for those patients with advanced kidney disease.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/living-with-kidney-disease-what-you-should-know/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kidney Disease and Insomnia</title>
		<link>http://kidneyfunction.org/kidney-disease-and-insomnia/</link>
		<comments>http://kidneyfunction.org/kidney-disease-and-insomnia/#comments</comments>
		<pubDate>Fri, 27 Nov 2009 22:11:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>
		<category><![CDATA[dialysis]]></category>
		<category><![CDATA[kidney failure]]></category>
		<category><![CDATA[insomnia]]></category>
		<category><![CDATA[kidney disease]]></category>
		<category><![CDATA[kidney problems]]></category>
		<category><![CDATA[trouble sleeping]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/?p=230</guid>
		<description><![CDATA[Many people are not aware of the link between kidney disease and insomnia. This isn&#8217;t too surprising, given the two seem unrelated on the surface. Although lack of sleep is often associated with heart disease, it can also be a red flag of early kidney disease.
In the beginning stages of renal disease, it is not [...]]]></description>
			<content:encoded><![CDATA[<p>Many people are not aware of the link between kidney disease and insomnia. This isn&#8217;t too surprising, given the two seem unrelated on the surface. Although lack of sleep is often associated with heart disease, it can also be a red flag of early kidney disease.</p>
<p>In the beginning stages of renal disease, it is not uncommon for patients to suffer from insomnia due to the body&#8217;s toxins invading the bloodstream and vital organs as the kidneys fail to properly process them.</p>
<p>As kidney disease progresses further, patients often experience high blood pressure as a subsequent result of failed kidney function. High blood pressure can put serious strain on the heart which in turn may cause chemicals in the brain to prevent proper rest.</p>
<p>For those patients that undergo dialysis treatments, they may experience trouble sleeping as a result of leg pain and cramps that tend to come at night. They may also feel the need to stretch or kick their legs at night which can disrupt their sleep (as well as the sleep of their partner). </p>
<p>Some kidney patients may be prescribed medication to treat their insomnia. It is critical that those suffering from kidney problems view insomnia as a potentially serious threat and not just an inconvenience.</p>
<p>Other alternatives to treat insomnia include <a href="http://portlandchronicle.com/2009/11-24/melatrol/">natural sleep aids</a> that can be acquired without a prescription. Consult your physician to determine which treatment option may be best for you.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/kidney-disease-and-insomnia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group &#8211; Corrected Proof</title>
		<link>http://kidneyfunction.org/phase-1-trial-of-adalimumab-in-focal-segmental-glomerulosclerosis-fsgs-ii-report-of-the-font-novel-therapies-for-resistant-fsgs-study-group-corrected-proof/</link>
		<comments>http://kidneyfunction.org/phase-1-trial-of-adalimumab-in-focal-segmental-glomerulosclerosis-fsgs-ii-report-of-the-font-novel-therapies-for-resistant-fsgs-study-group-corrected-proof/#comments</comments>
		<pubDate>Fri, 27 Nov 2009 06:54:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/phase-1-trial-of-adalimumab-in-focal-segmental-glomerulosclerosis-fsgs-ii-report-of-the-font-novel-therapies-for-resistant-fsgs-study-group-corrected-proof/</guid>
		<description><![CDATA[Background: Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to current treatment regimens are at high risk of progression to end-stage kidney disease. Antifibrotic agents, such as tumor necrosis factor α antagonists, are a promising strategy to slow or halt the decline in renal function, based on preclinical and clinical data.Study Design: Phase 1 clinical [...]]]></description>
			<content:encoded><![CDATA[<p>Background: Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to current treatment regimens are at high risk of progression to end-stage kidney disease. Antifibrotic agents, such as tumor necrosis factor α antagonists, are a promising strategy to slow or halt the decline in renal function, based on preclinical and clinical data.Study Design: Phase 1 clinical trial to assess the pharmacokinetics, tolerability, and safety of adalimumab, a human monoclonal antibody to tumor necrosis factor α.Setting &amp; Participants: 10 patients (4 male and 6 female) aged 16.8 ± 9.0 years with an estimated glomerular filtration rate of 105 ± 50 mL/min/1.73 m2 were studied.Intervention: Adalimumab, 24 mg/m2, every 14 days for 16 weeks (total, 9 doses).Outcomes: Pharmacokinetic assessment, tolerability, and safety.Measurements: Estimated glomerular filtration rate, proteinuria, and pharmacokinetic assessment after initial dosing and steady state.Results: Pharmacokinetic evaluation indicated that the area under the curve was decreased by 54% (P &lt; 0.001) and clearance was increased by 160% (P &lt; 0.01) in patients with resistant FSGS compared with healthy controls and patients with rheumatoid arthritis. Adalimumab was well tolerated with no serious adverse events or infectious complications attributable to the drug. Proteinuria decreased by ≥ 50% in 4 of 10 treated patients.Limitations: Insufficient power to assess the safety or efficacy of adalimumab therapy for patients with resistant FSGS.Conclusions: Pharmacokinetic assessment showed increased clearance of adalimumab in patients with resistant primary FSGS and validated the need to evaluate the disposition of novel therapies for this disease to define appropriate dosing regimens. The study provides a rationale to evaluate the efficacy of adalimumab as an antifibrotic agent for resistant FSGS in phase 2/3 clinical trials.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/phase-1-trial-of-adalimumab-in-focal-segmental-glomerulosclerosis-fsgs-ii-report-of-the-font-novel-therapies-for-resistant-fsgs-study-group-corrected-proof/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Crystal-Induced Kidney Disease in 2 Kidney Transplant Recipients &#8211; Corrected Proof</title>
		<link>http://kidneyfunction.org/crystal-induced-kidney-disease-in-2-kidney-transplant-recipients-corrected-proof/</link>
		<comments>http://kidneyfunction.org/crystal-induced-kidney-disease-in-2-kidney-transplant-recipients-corrected-proof/#comments</comments>
		<pubDate>Sat, 07 Nov 2009 22:34:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/crystal-induced-kidney-disease-in-2-kidney-transplant-recipients-corrected-proof/</guid>
		<description><![CDATA[Crystal-induced kidney disease refers to kidney injury caused by intratubular crystal deposition of calcium salts, medications, or other chemicals. The major risk factors for crystal deposition include hypercalcemia and/or hypercalciuria, hyperoxalosis and/or hyperoxaluria, and increased serum and/or urinary phosphate levels. The risk of crystal-induced kidney disease is increased further in the presence of hypovolemia and [...]]]></description>
			<content:encoded><![CDATA[<p>Crystal-induced kidney disease refers to kidney injury caused by intratubular crystal deposition of calcium salts, medications, or other chemicals. The major risk factors for crystal deposition include hypercalcemia and/or hypercalciuria, hyperoxalosis and/or hyperoxaluria, and increased serum and/or urinary phosphate levels. The risk of crystal-induced kidney disease is increased further in the presence of hypovolemia and urinary concentration, changes in urinary pH, and decrease in level of urinary inhibitors of crystallization, such as citrate, magnesium, and pyrophosphate. In the case of calcium phosphate crystal deposition, use of angiotensin-converting enzyme inhibitors is considered an additional risk factor. In addition to calcium salts and uric acid, drugs such as sulfonamides, foscarnet, methotrexate, triamterene, phosphate-containing bowel preparations, orlistat, ciprofloxacin, and indinavir can cause crystal-induced kidney disease. Clinical manifestations of crystal-induced kidney disease are wide ranging, from no symptoms to flank pain, hematuria, sterile pyuria, crystalluria, and reduced kidney function. Although crystal-induced kidney disease is well documented in native kidneys, its occurrence in kidney allografts is not. We report 2 cases of crystal-induced kidney disease in transplant recipients that resulted in kidney failure.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/crystal-induced-kidney-disease-in-2-kidney-transplant-recipients-corrected-proof/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Importance of Calcium and Phosphorus</title>
		<link>http://kidneyfunction.org/importance-of-calcium-and-phosphorus/</link>
		<comments>http://kidneyfunction.org/importance-of-calcium-and-phosphorus/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 03:38:17 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>
		<category><![CDATA[kidney failure]]></category>
		<category><![CDATA[calcium]]></category>
		<category><![CDATA[diet]]></category>
		<category><![CDATA[kidney health]]></category>
		<category><![CDATA[phosphorus]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/?p=224</guid>
		<description><![CDATA[Calcium is the most abundant element in the human body. 95% of your body&#8217;s calcium can be found in your bones and teeth. The second most abundant element in the human body is phosphorus. A large percentage of your body&#8217;s phosphorus is combined with the calcium in your skeletal structure. A lesser amount of phosphorus [...]]]></description>
			<content:encoded><![CDATA[<p>Calcium is the most abundant element in the human body. 95% of your body&#8217;s calcium can be found in your bones and teeth. The second most abundant element in the human body is phosphorus. A large percentage of your body&#8217;s phosphorus is combined with the calcium in your skeletal structure. A lesser amount of phosphorus lies in the soft tissues and fluids of your body.</p>
<p>Both calcium and phosphorus are required for the proper formation of bones. The body cannot utilize calcium whatsoever unless active Vitamin D is present. Because non-functioning kidneys cannot activate Vitamin D, calcium from food eaten by someone with non-functioning kidneys cannot be absorbed adequately. Subsequently, your body&#8217;s blood calcium level can drop dramatically.</p>
<p>Phosphorus is known to build up in the bodies of patients with non-functioning kidneys which can result in a decrease in the level of blood calcium present. When calcium levels drop, the parathyroid glands secrete the parathyroid hormone which causes calcium to be released from the bones and then sent back into the bloodstream. This release of calcium from your bones may cause them to become weak or brittle, and if this process continues for a prolonged period of time, bones may break.</p>
<p>A doctor monitors this delicate relationship between phosphorus and calcium and may prescribe a calcium supplement. Foods high in phosphorus should be avoided altogether. Additionally, phosphate binders (like calcium salts) may be prescribed in order to prevent the phosphorus in your food from being absorbed into your body.</p>
<p><strong>Why Do I Need to Restrict My Phosphorus Intake?</strong><br />
Due to the fact that high levels of phosphorus in your bloodstream can result in your bones being deprived of much needed calcium, it is of the utmost importance that phosphorus be restricted from your diet. Also, high levels of phosphorus may potentially combine with calcium and deposit in the soft tissues such as your blood vessels, skin, and lungs. If this occurs, you may experience joint pains, itching, and/or eye irritation. </p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/importance-of-calcium-and-phosphorus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fanconi Syndrome and CKD in a Patient With Paroxysmal Nocturnal Hemoglobinuria and Hemosiderosis &#8211; Corrected Proof</title>
		<link>http://kidneyfunction.org/fanconi-syndrome-and-ckd-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-and-hemosiderosis-corrected-proof/</link>
		<comments>http://kidneyfunction.org/fanconi-syndrome-and-ckd-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-and-hemosiderosis-corrected-proof/#comments</comments>
		<pubDate>Wed, 21 Oct 2009 15:28:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/fanconi-syndrome-and-ckd-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-and-hemosiderosis-corrected-proof/</guid>
		<description><![CDATA[Fanconi syndrome and chronic kidney disease associated with paroxysmal nocturnal hemoglobinuria is rarely reported. We describe a 51-year-old woman with glomerular filtration rate decrease and hypokalemia, glucosuria, and proteinuria during a 4-year period. Paroxysmal nocturnal hemoglobinuria was diagnosed 17 years earlier, and she has received multiple blood transfusions because of hemolytic episodes during the last [...]]]></description>
			<content:encoded><![CDATA[<p>Fanconi syndrome and chronic kidney disease associated with paroxysmal nocturnal hemoglobinuria is rarely reported. We describe a 51-year-old woman with glomerular filtration rate decrease and hypokalemia, glucosuria, and proteinuria during a 4-year period. Paroxysmal nocturnal hemoglobinuria was diagnosed 17 years earlier, and she has received multiple blood transfusions because of hemolytic episodes during the last 5 years. Deteriorating kidney function and persistent Fanconi syndrome were accompanied by a progressive increase in serum ferritin levels. Laboratory studies showed proximal renal tubular acidosis, hypophosphotemic hyperphosphaturia, normoglycemic glucosuria, and aminoaciduria. Serologic testing, tumor markers, Bence-Jones protein, and heavy-metal screening results were negative. Abdominal magnetic resonance imaging showed characteristic features of iron deposition in the bilateral renal cortices. Kidney biopsy showed chronic interstitial nephritis with prominent hemosiderin deposition in the proximal tubules. With potassium citrate, calcitriol, and deferoxamine therapy, Fanconi syndrome persisted, but kidney function was stable. Renal hemosiderosis secondary to both chronic repetitive hemolytic episodes and transfusion-related iron overload in patients with paroxysmal nocturnal hemoglobinuria can lead to Fanconi syndrome and chronic kidney disease.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/fanconi-syndrome-and-ckd-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-and-hemosiderosis-corrected-proof/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypertension in Hemodialysis Patients: The Role of Antihypertensive Medications &#8211; Corrected Proof</title>
		<link>http://kidneyfunction.org/hypertension-in-hemodialysis-patients-the-role-of-antihypertensive-medications-corrected-proof/</link>
		<comments>http://kidneyfunction.org/hypertension-in-hemodialysis-patients-the-role-of-antihypertensive-medications-corrected-proof/#comments</comments>
		<pubDate>Tue, 13 Oct 2009 17:55:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Renal Info]]></category>

		<guid isPermaLink="false">http://kidneyfunction.org/hypertension-in-hemodialysis-patients-the-role-of-antihypertensive-medications-corrected-proof/</guid>
		<description><![CDATA[Commentary on Heerspink HJL, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668):1009-1015.
]]></description>
			<content:encoded><![CDATA[<p>Commentary on Heerspink HJL, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668):1009-1015.</p>
]]></content:encoded>
			<wfw:commentRss>http://kidneyfunction.org/hypertension-in-hemodialysis-patients-the-role-of-antihypertensive-medications-corrected-proof/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
